As a therapeutic indication, rheumatoid arthritis gets more love from investors, but another painful joint disorder has come to the fore as well, and Savient Pharmaceuticals Inc. is the company they talk about when they talk about gout. (BioWorld Financial Watch)

Under-a-dollar shares of DOR BioPharma Inc. lost more than half their value after the FDA issued a not approvable letter for orBec, a steroid-sparing agent, citing the need for further efficacy and safety data in patients with gastrointestinal graft-vs.-host disease, a complication of hematopoietic cell transplantation. (BioWorld Today)